American service members pledge to safeguard us from global dangers, which sometimes requires the ultimate sacrifice. In return, we honor the legacy of President Lincoln, with the commitment to support those who have suffered in battle, including women who have faced their own struggles.
However, there are emerging policies from the Trump administration that, despite good intentions, may inadvertently jeopardize the welfare of veterans.
Trump aims to alleviate prescription drug costs for everyone, including active-duty personnel, veterans, and civilians. His latest proposal suggests linking U.S. drug prices to those in countries with lower costs.
This approach might sound appealing, yet it risks harming the U.S. biotechnology sector. Instead of compelling other nations to pay fair prices for medications largely innovation-driven here, it would keep prices artificially low abroad, eroding our competitive edge.
Beyond that, it also raises concerns over national security by weakening our pharmaceutical leadership while jeopardizing the health of veterans suffering from complex illnesses.
To grasp these issues, it’s crucial to understand the lengthy and costly journey of drug development, with the average new drug taking upwards of ten years and over two billion dollars to come to market.
Companies rely on market-driven pricing to recoup such hefty investments. As the largest developed country that allows these market dynamics, the U.S. has become a leader in healthcare innovation.
Most of the global investments in life science R&D originate from U.S. firms.
Yet, if we adopt the proposed pricing strategy, it may halt investment, as companies would be forced to abandon significant research endeavors to stay financially afloat.
This is particularly alarming for veterans, many of whom are prone to chronic health conditions.
Take mental health, for instance. Recent data indicated that over a quarter of veterans are likely facing mental health issues or substance use disorders. Furthermore, it’s estimated that 20% of deployed veterans encounter post-traumatic stress disorder, and about 15% struggle with depression.
On the physical health front, veterans can also face heightened risks for several cancers. For example, those exposed to burn pits while serving often see increased risks for pancreatic cancer, which has one of the highest mortality rates among cancers.
Vietnam veterans exposed to Agent Orange have been linked to various serious conditions, including non-Hodgkin’s lymphoma and Parkinson’s disease—disorders for which treatment options are limited. Veterans depend on pharmaceutical companies to find cures for these ailments, yet a lack of innovation under such pricing rules would endanger their health.
In fact, the development of new treatments may shift away from the U.S. entirely, possibly favoring countries like China. The Chinese Communist Party prioritizes life sciences and invests significantly in drug development, which has led to rapid advancements in their clinical research area.
Currently, they manage a growing share of new clinical trials, posing a competitive threat as our drug pricing strategies inadvertently place us at a disadvantage.
This could mean that U.S. veterans and other patients may increasingly rely on medications developed by state-supported companies in China, raising serious concerns about national security.
Thankfully, there are ways Trump can prioritize the health of veterans while also managing drug prices. Reducing the influence of pharmacy benefit managers and negotiating fair pricing with foreign countries could alleviate costs without stifling innovation.
Trump has shown a commitment to caring for American veterans, recently issuing an order aimed at enhancing services at the Department of Veterans Affairs. Still, his push for a pricing strategy that mirrors those of other countries could unintentionally place our heroes at risk.
Veterans have already made significant sacrifices for our nation. They deserve a drug pricing approach that prioritizes their health, preventing further sacrifice.
